Oval cell proliferation precedes neoplasia in many rodent models of hepatocellular carcinoma and prevention of this proliferative response can reduce the risk of subsequent carcinoma. This study aimed to determine whether a selective cyclo-oxygenase-2 (COX-2) inhibitor, SC-236, affects (1) the oval cell response to liver injury in a mouse model of hepatocarcinogenesis and (2) an oval cell line. Four-week-old mice were fed either normal chow or a choline deficient, 
INTRODUCTION
Hepatocellular carcinoma (HCC) is the major malignancy complicating chronic liver disease [1] .
Preventative approaches to therapy are limited and treatment by resection, chemotherapy or transplantation is expensive and has limited success with high recurrence rates [2] [3] [4] . Thus, new therapeutic approaches for the prevention of HCC are required. Emerging evidence suggests that HCC may arise by the transformation of adult hepatic progenitor cells, called "oval" cells in mice and "intermediate hepatobiliary" cells in humans [5] [6] [7] . Oval cells have the capacity to differentiate into hepatocytes and biliary epithelial cells during liver regeneration [8] [9] [10] [11] . Oval cells proliferate in response to liver injury in the early stages of most rodent models of hepatocarcinogenesis and are strongly associated with the presence of inflammation [12] [13] [14] [15] [16] .
They share antigenic epitopes with liver tumour cells, including M 2 -pyruvate kinase (M2PK) and alpha feto-protein (AFP) [17] [18] [19] . In humans, hepatic progenitor cells proliferate following chronic liver injury due to chronic viral hepatitis, alcoholic liver disease or metabolic liver conditions, and their numbers increase in direct proportion with the disease severity [20, 21] . We have shown that when mice have an attenuated M2PK-positive oval cell response they have a reduced incidence of HCC following prolonged liver injury via a tumour necrosis factor (TNF) dependent mechanism [22] . As TNF is a pro-inflammatory cytokine, this suggests that antiinflammatory agents may be effective in inhibiting the proliferation of oval cells and, therefore, HCC formation.
The cyclo-oxygenase (COX) isozymes COX-1 and COX-2 mediate the conversion of arachidonic acid into a range of prostaglandins that have effects on inflammation and carcinogenesis. Whilst COX-1 plays a constitutive homeostatic role, COX-2 is induced locally during inflammation and carcinogenesis [23] [24] [25] . COX-2 expression is up-regulated in subjects with chronic hepatitis, cirrhosis and HCC, and is expressed in non-parenchymal cells during experimental hepatocarcinogenesis [26] [27] [28] [29] . Investigations now show that the administration of a selective COX-2 inhibitor (SC2I) may reduce the incidence of breast, colon, pancreatic, skin and stomach tumours [30, 31] . Recent studies have also shown that SC2Is can reduce COX-2 expression and the development of pre-neoplastic foci, fibrosis and HCC in rats fed a choline deficient diet [28, [32] [33] [34] [35] . The mechanism of this anti-tumourigenic effect of SC2Is was not explored in these studies, however other reports have shown that COX-2 inhibitors are able to induce apoptosis in liver tumour cells [36] [37] [38] [39] . We hypothesized that SC2Is may modulate hepatocarcinogenesis by selectively reducing the hepatic oval cell response during the early stages of liver disease. Thus, the aim of this study was to determine the effect of an SC2I, SC-236, on oval cell numbers during pre-neoplastic liver injury in mice fed a carcinogenic diet, and their ability to directly modulate oval cell behaviour in vitro.
MATERIALS AND METHODS

Experimental design
Four-week old C57Bl/6J mice were housed under specific pathogen free conditions, in accordance with the guidelines of the National Health and Medical Research Council of Australia and the Animal Ethics Committee of the University of Western Australia. Mice were fed either normal chow and drinking water (control diet) or choline deficient chow (ICN, USA) and drinking water supplemented with 0.165% ethionine (Sigma, USA) (CDE diet). To study the effect of SC2I administration, mice were given either SC-236 (Pfizer, USA; 5 mg/kg/day) or vehicle alone (0.05% Tween 20 and 0.95% polyethylene glycol 200; Sigma-Aldrich, USA) in drinking water, according to the method previously described [40] . Mice were divided into 4 groups and fed: (1) normal chow + SC-236, (2) CDE diet, (3) CDE diet + vehicle or (4) CDE diet 6 + SC-236 (CDE+D). At 2, 4, 12 and 52 weeks, 5-7 mice from each group were sacrificed and their livers and serum collected. Throughout the experiments there were no significant differences between (a) CDE and (b) CDE + vehicle so these groups were combined and named CDE-D.
Tissue and serum preparation
Mice were anaesthetized and whole bloods taken via cardiac puncture for serum collection.
Whole body and liver weights were recorded at the time of sacrifice. The liver was perfused with phosphate-buffered saline (PBS) and portions of liver tissue (approximately 5 mm 3 ) were either snap frozen in liquid nitrogen or fixed in neutral buffered formalin for 24 hours and embedded in paraffin. Serum aspartate aminotransferase (AST) activity was measured using a kit, according to the manufacturer's instructions (Sigma-Aldrich, USA).
Histopathology and immunohistochemistry
For histology, 4 µm sections were cut from paraffin embedded liver and stained with hematoxylin and eosin (H&E). Sections from 52 week samples were stained with H&E and
Masson's trichrome [41] and examined blindly by a histopathologist (Dr. Ross Glancy, Fremantle
Hospital, Perth, Australia) for morphology, dysplasia and fibrosis. Five µm frozen sections were stained using A6 antibody (1:30, gift from Dr. V. Factor) and detected using a two-step indirect method [42] . Immunohistochemistry (IHC) on formalin-fixed liver was performed using [20] . Oval cells were identified and scored using a combination of morphological and immunohistochemical criteria as previously described [42] . The number of oval cells and COX-2-positive cells was determined by counting 10 peri-portal non-overlapping fields at 40X magnification. Cell numbers were expressed as the average percentage of total cell number per field of view. Double IHC was performed as described in Tian et al [14] , using antibodies directed against COX-2 
In vivo apoptosis studies
Apoptosis was detected in 4 µm paraffin embedded sections using the DeadEnd Colorimetric Prostaglandin E 2 (PGE 2 ) measurement PGE 2 concentration in liver tissue and culture media was determined using an immunoassay kit following the manufacturer's instructions (Cayman Chemicals, USA). For liver tissue, 50 mg of frozen tissue was homogenised in 0.5 mL of homogenisation buffer (0.1 M Tris-HCl, 10 µM indomethacin) on ice. The homogenate was centrifuged for 10 min at 16,000 g and the supernatant was removed to measure the PGE 2 content using a PGE 2 purification kit (Cayman Chemicals, USA). 50 µL of culture media was used to measure PGE 2 concentration.
In vitro oval cell studies
A well characterized immortalized murine oval cell line (termed PIL-2), which exhibits phenotypic similarities with oval cells in vivo, was used for the in vitro work [19] . PIL-2 cells are immuno-reactive for the hepatocyte markers albumin and transferrin and the oval cell markers AFP, A6 and M2PK. They are capable of differentiating into both hepatic and biliary lineages (unpublished results) and exhibit increased proliferation in response to increasing concentrations of serum [43] . PIL-2 cells were maintained in culture as previously described [19] . For analysis of COX-2 expression, primary oval cells were isolated from the livers of mice fed the CDE diet for 2 weeks as previously described [44] . For growth assays, PIL-2 cells were seeded in 96 well microtitre plates at medium density of 3,000 cells/well. Following adherence, cells were exposed to media containing either DMSO alone (vehicle), LY-294002 (an inhibitor of phosphatidylinositol-3 kinase and Akt phosphorylation, Sigma, USA) or SC-236 dissolved in DMSO at various concentrations (0.5 to 100 µM) for 24 hours. To determine whether exogenous PGE 2 could prevent the effects of SC-236, separate experiments were also conducted with the addition of PGE 2 (MO Biomedicals, USA) at various concentrations (0 to 50 µM). Numbers of viable cells present at the end of the experiment were determined by MTT-based assay [43] . A6
immunocytochemistry was performed as previously described [19] .
In vitro apoptosis study
PIL-2 cells were cultured in the presence of either vehicle alone or 25 µM of SC-236 for 6 hours.
Cells undergoing apoptosis were identified using Annexin V-FITC (Molecular Probes, USA)
according to the manufacturer's protocol.
RNA isolation and RT-PCR
Total RNA was isolated from whole liver or cultured cells using TRIzol (Invitrogen, USA)
according to the manufacturer's instructions. RNA was converted to cDNA using the Thermoscript Reverse Transcription System (Invitrogen, USA) according to the instructions of the manufacturer. PCR was performed using specific primers directed against murine COX-2 (forward primer: 5' AAAACCGTGGGGAATGTATGAGCAC 3', reverse primer: 5' AAACTTCGCAGGAGGGGGATGTTG 3') or β-Actin (forward primer: 5' CTGGCACCACACCTTCTA 3' reverse primer: 5' GGGCACAGTGTGGGTGAC 3'). For analysis of whole liver COX-2 levels, quantitative PCR was performed in real time using a RotorGene 2000 (Corbett, Australia) incorporating SYBR green to measure the formation of double stranded amplicons. Data were normalised against a plasmid construct containing the COX-2 fragment, generated exactly as previously described [44] . Quantitation data for COX-2 PCR was normalised against that of β-Actin. PCR products were separated using agarose gel electrophoresis and stained using ethidium bromide. Resultant bands were compared to a molecular weight marker to confirm the products were the expected size. Cruz, USA) at room temperature for 1 hour, and washed with PBS three times. Bound antibodies were detected using ECL Plus (Amersham, UK) and visualized using the Versadoc ™ Imager (Biorad, USA). Band densities were quantified using Quantity One software, version 4.5.0 (Biorad, USA).
Western immunoblotting
Statistical methods
Each in vitro experiment was performed three times and in duplicate. Data are reported as the mean + SEM. Comparisons between groups were performed using unpaired t-test or Fisher's exact test (GraphPad Prism version 4.00 for Windows, GraphPad Software, USA). Data were deemed to be significantly different when P < 0.05.
RESULTS
Early changes following administration of the CDE diet. At 2 and 4 weeks, mice fed the CDE diet exhibited mild macrovesicular steatosis and inflammatory infiltration consistent with previously published observations [42] . There were no discernible differences in these parameters between CDE fed mice treated with or without SC-236. Serum AST levels were elevated at 2 weeks in mice fed the CDE diet but were not different from control diet animals thereafter ( Figure 1 ). Administration of SC-236 did not affect the total body or liver weights (data not shown), or serum AST levels of the CDE fed mice (Figure 1 ). The hepatic PGE 2 content of mice fed the control diet was 481±18 pg/mg protein. Administration of the CDE diet for 2 weeks increased the PGE 2 content to 863±35 pg/mg protein (P < 0.05). Treatment with SC-236 did not affect hepatic PGE 2 content in mice fed the CDE diet (800±30 pg/mg protein).
SC-236 administration decreases CDE-mediated pathologies.
Mice fed the CDE diet for 52 weeks exhibited marked hepatocyte nuclear atypia and dysplasia compared with age-matched mice receiving a normal diet (Figure 2A and B) . Mice fed the CDE diet developed AFP-positive foci ( Figure 2C ). Some also developed large white nodular lesions on their livers ( Figure 2D) which stained positively for A6. Sixty percent (8 of 14) of CDE-fed mice exhibited peri-cellular fibrosis ( Figure 2E ) while none of the CDE-fed mice also receiving SC-236 had fibrosis ( Figure   2F , P < 0.05). Overall SC-236 administration reduces the incidence of a range of pathologies which develop during long term CDE diet administration (Table 1) . There have been several studies reporting a reduction in the grade and incidence of fibrosis, preneoplastic foci and hepatocarcinogenesis following administration of various COX-2 inhibitors in rats fed a choline deficient diet [28, [32] [33] [34] [35] . However, these studies did not investigate the specific effects of an SC2I on oval cells, even though it is well established that oval cell proliferation is a key feature of liver injury in rodents fed a choline deficient diet [45] [46] [47] . Our Our findings are consistent with previous work demonstrating that a reduction in the number of oval cells is associated with a reduced incidence of hepatocarcinogenesis in mice fed the CDE diet [22] . In the context of human chronic liver disease, these results are of considerable relevance, since the risk of HCC is paralleled by changes in the number of hepatic progenitor cells [20] . Whether hepatic progenitor cells directly give rise to HCC remains unresolved, however they are at least closely associated with diverse liver diseases and pathologies that generally occur in association with HCC [48, 49] including small cell dysplasia [50] , parenchymal inflammation [15] and fibrosis [20, 21] . Therefore, hepatic progenitor cells represent a population that reflects the extent of liver damage and the likelihood for hepatocarcinogenesis. The administration of pharmaceutical agents such as SC2I may ultimately prove useful in the reduction of HCC risk associated with liver progenitor cell proliferation.
SC-
We recently established a transformed murine oval cell line (PIL-2) that exhibits morphologic and functional characteristics consistent with oval cells in vitro and in vivo [19] . In summary, our data confirm the inhibitory effects of SC2Is on hepatocarcinogenesis and suggest that this may be mediated by induction of oval cell apoptosis during the early stages of disease progression. We suggest that pharmaceutical agents with properties exhibited by SC2Is may be useful as preventative treatment strategies for HCC in patients with chronic liver disease. Fig. 2.   Fig. 3 . 
